Using Metabolomics and Imaging to Track RLT Response
Radioligand therapy (RLT) represents a paradigm shift in precision oncology, delivering targeted radiation directly to cancer cells while minimizing damage to healthy tissue. Cell line-derived xenograft (CDX) models serve as essential platforms for RLT development,...
Mapping Signaling Drivers of Antibody Drug Conjugate Resistance
Antibody-drug conjugate (ADC) resistance represents one of the most formidable challenges in precision oncology, with clinical failures often attributed to our limited understanding of the dynamic molecular mechanisms underlying therapeutic escape. Panome Bio’s...
A Metabolic Blueprint for Synergistic Cancer Therapy
In the fight against cancer, single-agent treatments often hit a wall as tumors adapt and develop resistance. This is especially true for aggressive cancers like non-small-cell lung cancer (NSCLC) with KRAS and LKB1 mutations, a hard-to-treat subtype. These challenges...